Sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers have been reported in a Humanwell Healthcare (Group) Co. Ltd. patent as potentially useful for the treatment of pain.
Fusion Biotechnology and Ulsan National Institute of Science and Technology (UNIST) have prepared sugar-linked imidazoline derivatives and their micelles reported to be useful for the treatment of age-related diseases.
A University of Texas System patent describes new allosteric modulators of 5-HT2A and/or 5-HT2C receptors potentially useful for the treatment of obesity, substance abuse and dependence, mood and seizure disorders.
Kalivir Immunotherapeutics Inc. has announced FDA clearance of an IND application for a phase I study of ASP-1012 (formerly VET2-L2) in participants with locally advanced or metastatic solid tumors. The trial is expected to begin in the first quarter of next year.
Skyhawk Therapeutics Inc. has obtained Australian human research ethic committee (HREC) approval to conduct a phase I trial of SKY-0515 for Huntington’s disease.
Researchers from Loxo Oncology at Eli Lilly and Co. recently reported the discovery and preclinical evaluation of a new highly potent and selective pan-KRAS inhibitor, LY-4066434, being developed for the treatment of cancer.
The Finnish regulatory agency (FIMEA) has approved Kancera AB’s application to conduct a phase I study of KAND-145, the company’s second-generation fractalkine-blocking candidate drug for cancer.
Borrelia burgdorferi, one of the bacteria species causing Lyme disease, has a small genome and is therefore highly dependent on its hosts to obtain many necessary metabolites. Its small genome makes B. burgdorferi an attractive candidate for developing narrow-spectrum antibiotics targeting those essential genes. The use of narrow-spectrum antibiotics may reduce the risk of side effects and the spread of antimicrobial resistances compared with traditional, long-term antibiotic treatments.
Researchers from Hefei Institutes of Physical Science Chinese Academy of Sciences and affiliated organizations have reported the discovery of IHMT-PI3K-455, a novel potent and selective PI3Kγ/δ dual inhibitor as a potential anticancer agent.
Endogena Therapeutics Inc. has received FDA clearance of its IND application for EA-2351 for geographic atrophy, an advanced form of age-related macular degeneration (AMD).
RSS
